SCHEMBL14800898

SCHEMBL14800898

FC(F)Oc1ccc(Nc2ncc(C=Cc3ccc(OCc4ccccc4)cc3)cn2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 1/20 0.47
▸ GSK3B P49841 2/20 0.46
▸ BACE1 P56817 2/20 0.46
▸ MRGPRX4 Q96LA9 1/20 0.43
▸ CHEK2 O96017 1/20 0.42
▸ EGFR P00533 1/20 0.42
▸ ERBB2 P04626 1/20 0.42
▸ ROS1 P08922 1/20 0.42
▸ FLT3 P36888 1/20 0.42
▸ ERBB4 Q15303 1/20 0.42
▸ AURKB Q96GD4 1/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.42
▸ MKNK2 Q9HBH9 1/20 0.42
▸ SYK P43405 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ PPARG P37231 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14800896 1.00 LCK (0.47) LCKGSK3BBACE1MRGPRX4CHEK2
SCHEMBL8147428 0.77 MRGPRX4 (0.63) MRGPRX4SMN1; SMN2MAPTRAB9ALMNA
SCHEMBL14800933 0.75 SYK (0.46) GSK3BSYKMAPTLMNANPC1
SCHEMBL14800724 0.74 ROCK1 (0.48) MRGPRX4SYKMAPTLMNAMEN1
SCHEMBL20024692 0.74 LCK (0.77) LCKGSK3BBACE1SMN1; SMN2MAPT
SCHEMBL14786203 0.74 LCK (0.77) LCKGSK3BBACE1SMN1; SMN2MAPT
SCHEMBL15145210 0.73 KMT2A (0.48) CHEK2EGFRERBB2ROS1FLT3
SCHEMBL14800659 0.72 GRM5 (0.46) GSK3BSYKMAPTLMNAMEN1
SCHEMBL27785731 0.72 CHEK1 (0.46) LCKGSK3BEGFRROS1FLT3
SCHEMBL8913590 0.72 LCK (0.81) LCKGSK3BBACE1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760843-B1 SELECTIVE NR2B ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2016-03-02 — — EP disclosed
US-8841301-B2 Selective NR2B antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-23 — — US disclosed
EP-2760843-A2 SELECTIVE NR2B ANTAGONISTS Bristol-Myers Squibb Company (US) 2014-08-06 — — EP disclosed
WO-2013048949-A2 SELECTIVE NR2B ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-04 — — WO disclosed
US-20130079338-A1 Selective NR2B Antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2013-03-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079338-A1 Selective NR2B Antagonists GRIN2B, GRIN2A, GRIN3A LCK 1701/4885GSK3B 2240/4885BACE1 1087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback